Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
Relapsed Multiple Myeloma|Refractory Multiple Myeloma
DRUG: OPN-6602|DRUG: Dexamethasone
Number and type of dose-limiting toxicities (DLTs), Through up to approximately 30 days following last dose of OPN-6602|Number and type of treatment-emergent adverse events (TEAEs), Through up to approximately 30 days following last dose of OPN-6602|Number of Participants With Clinical Laboratory Test Abnormalities, Number of participants who experienced a clinical laboratory test abnormality, including hematology and serum chemistry, and coagulation. Abnormalities considered are those Grade 3-4 events with a \>= 1 grade increase from baseline using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0., Through up to approximately 30 days following last dose of OPN-6602
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.